Buy CJC-1295 With DAC + Ipamorelin + GHRP-2 Online

What is Triple Blend?

Triple Blend is a three-peptide research formulation. It combines three distinct synthetic peptides in a single lyophilized vial. Each vial delivers 2mg of CJC-1295 with DAC, 2mg of Ipamorelin, and 2mg of GHRP-2. Total delivery is 6mg per vial.

CJC-1295 with DAC is a synthetic growth hormone-releasing hormone (GHRH) analogue conjugated to a Drug Affinity Complex that extends its research half-life via albumin binding. Ipamorelin is a synthetic pentapeptide studied as a selective ghrelin receptor (GHS-R1a) agonist. GHRP-2 (pralmorelin) is a synthetic hexapeptide, also a ghrelin receptor agonist, approved in Japan as a diagnostic agent but not FDA-approved in the US. In laboratory settings, these three compounds are investigated for their combined role in stimulating pituitary growth hormone release through two distinct pathways. This is a process central to the study of endocrine signaling in experimental models.

This lyophilized powder format is used in research settings as a delivery method that allows investigators to study combined GHRH-receptor and ghrelin-receptor pathway engagement without preparing and mixing three separate vials.

Disclaimer: Triple Blend is a research compound not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease. This product is strictly for laboratory research purposes only.

ATTENTION: This product is strictly for LABORATORY AND RESEARCH PURPOSES ONLY. Not for human or veterinary use.

Mechanism of Action of Triple Blend

CJC-1295 With DAC Working in Preclinical Models

CJC-1295 with DAC is thought to exert its effects primarily through agonism at the GHRH receptor on pituitary somatotroph cells, with its albumin-binding DAC modification extending stimulation duration relative to unmodified GHRH. The DAC moiety contains a maleimidopropionamide group that undergoes a Michael addition reaction with the free thiol (–SH) of serum albumin Cys-34 — the only free reactive thiol on circulating albumin — forming a stable thioether bond. This covalent albumin conjugation extends the half-life of CJC-1295 DAC to approximately 6–8 days by shielding the peptide from peptidase degradation and reducing renal clearance. 

Key mechanistic observations from laboratory studies:

• GHRH receptor agonism: CJC-1295 with DAC is thought to activate the GHRH receptor, extending pituitary GH-pulse amplitude.
• Albumin-binding half-life extension: The DAC modification is thought to extend research half-life from minutes to several days relative to native GHRH.

Ipamorelin Working in Preclinical Models

Ipamorelin is thought to work primarily through selective agonism at the ghrelin receptor (GHS-R1a), triggering pulsatile GH release with high selectivity.

Key mechanistic observations from laboratory studies:

• Selective ghrelin receptor agonism: Ipamorelin is thought to trigger GH-pulse initiation without significant elevation of ACTH, cortisol, or prolactin, distinguishing it from less selective secretagogues.
• GHRH-independent pathway: Studies have observed Ipamorelin working through a separate mechanism from GHRH-receptor agonists like CJC-1295, relevant to combination-research models.

GHRP-2 Working in Preclinical and Clinical Models

GHRP-2 is thought to work through ghrelin receptor (GHS-R1a) agonism, similar to Ipamorelin, but with a comparatively less selective secondary hormone profile.

Key mechanistic observations from laboratory studies:

• Ghrelin receptor agonism: GHRP-2 is thought to activate GHS-R1a, triggering pituitary growth hormone release.
• Secondary hormone effects: GHRP-2 co-stimulates ACTH and cortisol at GH-releasing concentrations — the defining mechanistic contrast with ipamorelin (which produces no ACTH/cortisol at 200× ED50; Raun et al. 1998, PMID 9849822). This co-stimulation must be controlled in any study with adrenal endpoints and is a key research design variable when comparing ipamorelin and GHRP-2 within this blend. 

Why combine CJC-1295 With DAC, Ipamorelin, and GHRP-2?

In laboratory settings, these three peptides are studied together because they are thought to operate through two mechanistically distinct but potentially synergistic pathways. CJC-1295 with DAC engages the GHRH receptor, while Ipamorelin and GHRP-2 both engage the ghrelin receptor through a separate pathway. Research combining a GHRH-receptor agonist with a ghrelin-receptor agonist has reported synergistic, rather than simply additive, pituitary GH release in published two-peptide studies. Whether adding a second ghrelin-receptor agonist (GHRP-2) alongside Ipamorelin changes this synergy has not itself been studied.

Chemical Properties of Triple Blend

CJC-1295 With DAC

Property	Detail
Molecular Formula	C165H269N47O46
Molecular Weight	3,647.8 g·mol⁻¹
CAS Number	446262-90-4
Purity	≥99% (HPLC verified, per batch COA)
Physical Form	White lyophilized powder
Storage	-20°C, protected from light and moisture
Classification	Research Use Only (RUO); WADA Prohibited  S2.2.4 (Growth Hormone Releasing Factors)

Ipamorelin

Property	Detail
PubChem CID	9831659
Molecular Formula	C38H49N9O5
Molecular Weight	711.85 g/mol
CAS Number	170851-70-4
Sequence	Aib-His-D-2Nal-D-Phe-Lys-NH2
Purity	≥99% (HPLC verified, per batch COA)
Physical Form	White lyophilized powder
Storage	-20°C, protected from light and moisture
Classification	Research Use Only (RUO); WADA Prohibited  S2.2.4 (Growth Hormone Secretagogues); FDA 503A Category 2 (ineligible for compounding)

GHRP-2

Property	Detail
PubChem CID	6918245
Molecular Formula	C45H55N9O6
Molecular Weight	817.97 g/mol
CAS Number	158861-67-7
Sequence	D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2
Purity	≥99% (HPLC verified, per batch COA)
Physical Form	White lyophilized powder
Storage	-20°C, protected from light and moisture
Classification	Research Use Only (RUO); WADA Prohibited  S2.2.4 (GH-Releasing Peptides); not FDA-approved in the US (approved in Japan as a diagnostic)

Blend Specification

Property	Detail
CJC-1295 With DAC per vial	2 mg
Ipamorelin per vial	2 mg
GHRP-2 per vial	2 mg
Total per vial	6 mg
Format	Lyophilized powder, single vial
Origin	USA-made

Research Applications of Triple Blend

1. GHRH and Ghrelin Receptor Synergy Research In preclinical models, combining a GHRH-receptor agonist (CJC-1295 with DAC) with a ghrelin-receptor agonist has been investigated for synergistic, rather than purely additive, pituitary GH-release research.
2. Selective vs. Non-Selective Secretagogue Comparison Research Ipamorelin's high receptor selectivity versus GHRP-2's broader secondary hormone profile makes this blend a tool for comparative secretagogue-selectivity research.
3. Growth Hormone/IGF-1 Axis Research All three peptides' stimulation of pituitary GH release supports downstream IGF-1 signaling research in endocrine models.
4. Analytical and Anti-Doping Detection Research Validated LC-MS/MS detection methods exist for all three compound classes, supporting analytical-chemistry and anti-doping laboratory research.

Risk and Handling Precautions

Risk Tier: MODERATE-HIGH

This rating reflects all three peptides' bioactive activity at GHRH- and ghrelin-receptor endocrine-signaling pathways in preclinical models, the explicit WADA-prohibited status of all three components, Ipamorelin's FDA 503A Category 2 status, and the absence of established human safety profiles for this specific three-peptide combination. Researchers must observe the following precautions at all times.

Handling Precautions: Triple Blend should be handled by trained laboratory personnel only. Use appropriate personal protective equipment (PPE) at all times, including gloves and eye protection. Avoid direct skin contact, inhalation, or accidental exposure during laboratory handling.

Exposure Risks: All three are research compounds with no approved safety profiles for human exposure as a combined formulation. No human toxicity data exists for this specific blend.

Storage: Store at -20°C in a dry, dark environment protected from light, heat, and moisture. Check the batch Certificate of Analysis for lot-specific guidance. Do not use if the seal has been compromised.

Toxicity and Data Limitations: No chronic toxicity data exist for this blend. All findings are from short-duration preclinical or single-agent clinical models, not from testing of this specific three-peptide co-blended formulation.

Why Choose BehemothLabz for Research-Grade Triple Blend?

BehemothLabz supplies Triple Blend for laboratory and research purposes. Every batch is independently tested by third-party laboratories for purity and identity. A Certificate of Analysis is publicly available for each lot. BehemothLabz does not self-certify.

The compound is USA-made and held to research-grade standards. It is available strictly to qualified researchers for use in controlled laboratory environments.

BehemothLabz Disclaimer

ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Please make sure you go through the Terms and Conditions and familiarize yourself with them, as it is important. Kindly research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.

Buying the product means you agree to our Terms and Conditions. You can contact our customer service team at support@behemothlabz.com if you are not fully satisfied with the product.

Triple Blend Research FAQs

Are all three peptides in this blend banned by WADA? 

Yes, all three. CJC-1295, Ipamorelin, and GHRP-2 are each explicitly named under WADA's Prohibited List, Section S2.2.4 (Growth Hormone Releasing Factors), prohibited at all times, in and out of competition. This is directly checkable at wada-ama.org/en/prohibited-list.

Is any peptide in this blend restricted from pharmacy compounding? 

Yes, at least Ipamorelin. As of FDA determinations documented in Pharmacy Compounding Advisory Committee materials (available at fda.gov), Ipamorelin has been placed in FDA 503A Category 2, meaning it is prohibited from use in compounded medications for human administration. None of the three peptides in this blend have ever received FDA approval for any human indication in the US.

How does CJC-1295 differ mechanistically from Ipamorelin and GHRP-2? 

CJC-1295 with DAC works through the GHRH receptor. Ipamorelin and GHRP-2 both work through the ghrelin receptor (GHS-R1a), a separate pathway. Combining a GHRH-receptor agonist with a ghrelin-receptor agonist has shown synergistic GH release in published two-peptide studies.

Can I verify the chemical identity of Ipamorelin and GHRP-2 independently? 

Yes. CJC-1295 with DAC is listed at PubChem CID 56841945 (CAS 446262-90-4, Formula C165H269N47O46, MW 3647.25 g/mol) — verify this batch's identity against both PubChem and the Certificate of Analysis. 

What does each vial deliver? 

Each vial delivers 2mg of CJC-1295 with DAC, 2mg of Ipamorelin, and 2mg of GHRP-2, for a combined 6mg total.

What purity standard does BehemothLabz provide for this blend? 

Every batch is independently tested by third-party laboratories. All three peptides are verified at ≥99% purity by HPLC analysis. A Certificate of Analysis confirming purity and molecular identity is available per lot.

How should Triple Blend be stored? 

Store at -20°C in a dry, dark environment protected from light, heat, and moisture. Check the batch Certificate of Analysis for lot-specific guidance. Do not use it if the seal has been compromised.

References

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. Available at: https://pubmed.ncbi.nlm.nih.gov/16352683/
2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. Available at: https://pubmed.ncbi.nlm.nih.gov/9849822/
3. Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316–1329. Available at: https://pubmed.ncbi.nlm.nih.gov/9893710/
4. World Anti-Doping Agency. The 2026 Prohibited List International Standard, Section S2.2.4. Available at: https://www.wada-ama.org/en/prohibited-list

Please click here to access instructions on how to make a payment.

How to Pay